Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 862 results for "eli lilly"

Eli Lilly and's (LLY) Outperform Rating Reaffirmed at Credit Suisse Group AG
Mideast Time

Eli Lilly to pay $960m for CoLucid, a Cambridge company with 7...

E-Mail Share via e-mail Facebook Twitter Google+ LinkedIn Comments Print The Boston Globe Tweet Share Thomas Mathers is chief executive Boston Globe, 20 hours ago
Elanco buys Boehringer animal health portfolio for $885M American Veterinary Medical Association, 30 minutes ago

389 images for eli lilly

Mideast Time, 4 hours ago
American Banking News, 22 hours ago
Post Online Media, 7 hours ago
Post Online Media, 1 day ago
American Banking News, 22 hours ago
SleekMoney, 3 days ago
Post Online Media, 6 days ago
American Banking News, 1 day ago, 2 days ago
BioSpace, 1 day ago

ELI LILLY AND : Findings in the Area of Chronic Kidney Disease Reported from Eli Lilly (Developing Treatments for Chronic Kidney Disease in the 21st Century)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Kidney Diseases and Conditions - Chronic Kidney Disease. According to news reporting originating from Indianapolis, Indiana, by NewsRx ...
 4 Traders2 hours ago Eli Lilly's Pricey Headache  Yahoo! Finance1 day ago Eli Lilly, Incyte announce US FDA extends review period for NDA for baricitinib to treat RA  PharmaBiz3 days ago FDA extends review period by three months for Lilly and Incyte's rheumatoid arthritis candidate baricitinib  Seeking Alpha3 days ago

SC TO-C - LILLY ELI & CO (0000059478) (Filed by)

Form SC TO-C - Written communication relating to an issuer or third party SEC Accession No. 0001193125-17-012400 Filing Date 2017-01-18 2017-01-18 16:51:02 Filing Date Changed 2017-01-18 Group Members PROCAR ACQUISITION CORP ...
 SEC Filings21 hours ago SC TO-C - CoLucid Pharmaceuticals, Inc. (0001348649) (Subject)  SEC Filings21 hours ago
Post Online Media

InMed Pharmaceuticals appoints Bott to board

Mr. Eric Adams reports INMED PHARMA APPOINTS ELI LILLY FINANCE EXECUTIVE TO BOARD OF DIRECTORS InMed Pharmaceuticals Inc. has appointed Martin Bott to its board of directors. The appointment of Martin Bott to InMed's Board of Directors ...
 Stockwatch2 hours ago InMed Pharmaceuticals, Inc. (IMLFF: OTCQB) | InMed Pharma Appoints Eli Lilly Finance Executive to Board of Directors -- CFN Media  OTC Markets4 hours ago INMED PHARMACEUTICALS : Pharma Appoints Eli Lilly Finance Executive to Board of Directors -- CFN Media  4 Traders5 hours ago InMed Pharma Appoints Eli Lilly Finance Executive to Board of Directors -- CFN Media  Yahoo! Finance4 hours ago

ELI LILLY AND CO : Blog Coverage Eli Lilly Announced Acquisition of CoLucid; Adds Lasmiditan to the Pain Management Portfolio

/ Active Wall St. blog coverage looks at the headline from Eli Lilly and Co. (NYSE: LLY ) and CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ) as both companies announced an agreement on January 18, 2017, where Lilly will acquire CoLucid for $46.50 per ...
 4 Traders5 hours ago Blog Coverage Eli Lilly Announced Acquisition of CoLucid; Adds Lasmiditan to the Pain Management Portfolio  Yahoo! Finance5 hours ago
Yahoo! Finance

Lilly brings migraine drug home with $960m acquisition

Eli Lilly has announced it is to shell out $960 million to snatch up CoLucid Pharmaceuticals and specifically its migraine treatment lasmiditan; Lilly will be reclaiming the drug after it licensed it to CoLucid following its discovery in 2005. We ...
 Pharmafile9 hours ago Lilly Regains Key Migraine Drug With $960 Million CoLucid Acquisition  Minyanville1 day ago

Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse

Credit Suisse is bullish on Eli Lilly and Co (NYSE: LLY ), saying the recent FDA delay on rheumatoid arthritis drug baricitinib is only a short-term setback for the pharma major . But, the brokerage acknowledges the stock could see some modest ...
 Benzinga.com2 days ago
Huffington Post Black Voices

CORRECTED-No new antidepressants in sight despite growing need, experts warn

(In 7th par, corrects manufacturer of Prozac to Eli Lilly) LONDON, Jan 11 (Reuters) - It is likely to be at least 10 years before any new generation of antidepressants comes to market, despite evidence that depression and anxiety rates are ...
 CNBC3 days ago New antidepressants 'at least 10yrs away'  Northern Territory News3 days ago New antidepressants at least 10yrs away  Daily Telegraph Australia3 days ago No new antidepressants in sight despite rising rates of depression  Irish Independent3 days ago

The Zacks Analyst Blog Highlights: Wells Fargo, Accenture, Eli Lilly, American Airlines and Domino's Pizza

For Immediate Release Chicago, IL January 17, 2017, 2016 announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial ...
 Yahoo! Finance2 days ago

Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended

Eli Lilly and Company LLY and partner Incyte Corporation INCY announced that the FDA has extended the time to review the company's New Drug Application (NDA) seeking approval of its pipeline candidate baricitinib for the treatment of rheumatoid ...
 Yahoo! Finance3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less